Decitabine

Decitabine
Clinical data
Trade names	Dacogen, Demylocan
Other names	5-aza-2'-deoxycytidine
AHFS/Drugs.com	Monograph
MedlinePlus	a608009
License data	US DailyMed: Decitabine;
Routes of; administration	Intravenous
ATC code	L01BC08 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	<1%
Elimination half-life	30 minutes
Identifiers
	IUPAC name 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one;
CAS Number	2353-33-5 ;
PubChem CID	451668;
IUPHAR/BPS	6805;
DrugBank	DB01262 ;
ChemSpider	397844 ;
UNII	776B62CQ27;
KEGG	D03665 ;
ChEBI	CHEBI:50131 ;
ChEMBL	ChEMBL1201129 ;
CompTox Dashboard (EPA)	DTXSID7030432 ;
ECHA InfoCard	100.017.355
Chemical and physical data
Formula	C8H12N4O4
Molar mass	228.208 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)C2)CO)N;
	InChI InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 ; Key:XAUDJQYHKZQPEU-KVQBGUIXSA-N ;
	(what is this?) (verify)

Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor.^[4] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML).^[5] Chemically, it is a cytidine analog.

^ "Summary Basis of Decision (SBD) for Dacogen". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Summary Basis of Decision (SBD) for Demylocan". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Dacogen EPAR". European Medicines Agency (EMA). 8 June 2006. Retrieved 4 June 2024.
^ "Decitabine". National Center for Biotechnology Information. Retrieved September 24, 2016.
^ "EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia". 2012-09-28. Retrieved 28 September 2012.

[1] "Summary Basis of Decision (SBD) for Dacogen". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[2] "Summary Basis of Decision (SBD) for Demylocan". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[3] "Dacogen EPAR". European Medicines Agency (EMA). 8 June 2006. Retrieved 4 June 2024.

[4] "Decitabine". National Center for Biotechnology Information. Retrieved September 24, 2016.

[EC-AML-5] "EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia". 2012-09-28. Retrieved 28 September 2012.

[1]

[2]

[3]

[4]

[5]

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Decitabine

Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.